Financial HealthCG ended the quarter with $688.4M in cash, cash equivalents, and marketable securities, which should fund the company into H1 2028 and to profitability.
Launch PotentialThere is confidence in creto's launch and uptake potential, which should outperform the early trajectory observed with other therapies.
Product DifferentiationCreto is meaningfully differentiated by its durability and safety data, which supports further upside for creto in additional indications and combinations with other therapies.